May 30, 2022 / 03:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q4 FY '22 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Ravi Agrawal, Head of Investor Relations for Glenmark Pharmaceuticals Limited. Thank you, and over to you, sir.
Ravi Agrawal - Glenmark Pharmaceuticals Limited - IR Officer
Yes. Thank you, moderator. Good morning, everyone, and a warm welcome to the Q4 FY '22 Results Conference Call of Glenmark Pharmaceuticals Limited.
Before we start the call, a review of operations of the company for the quarter and year ended March 31, 2022. For the fourth quarter of FY '22, Glenmark's consolidated revenue was at [INR 30,191 million], recording an increase of 5.6% year-on-year. For the year (inaudible) 31, 2022, Glenmark's consolidated revenue was at INR 123,049 million, recording an increase of 12.4% year-on-year.
Before we get into the detailed discussions on the businesses, the following were the key highlights
Full Year 2022 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
May 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers